Duration of Use of Highly Effective Reversible Contraception

Bayer

Status: Completed

Conditions: Pregnancy

Treatments: Drug: Mirena (Levonorgestrel IUS, BAY86-5028); Drug: Implanon/Nexplanon; Drug: ParaGard

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02414919

17714

Details and patient eligibility

About

To assess the proportion of women who use HERC for ≥2 years of duration

Enrollment: 13,880 patients

Sex: Female

Ages: 15 to 44 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

-Women who had an IUD or contraceptive implant inserted and removed within the University of Utah from January 1, 2004 to October 31, 2012

Trial design

13,880 participants in 1 patient group

HERC

Description:

Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon)

Treatment:

Drug: Mirena (Levonorgestrel IUS, BAY86-5028)

Drug: ParaGard

Drug: Implanon/Nexplanon